ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization

BACKGROUND: Multitarget tyrosine kinase inhibitors (mTKIs) such as Regorafenib and Sorafenib have already been approved for the treatment of many solid tumours. However, the efficacy of mTKIs in colorectal cancer (CRC) is limited; the underlined mechanism remains largely elusive. Our study was aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Xiaolin, Liu, Ruiqi, Liao, Yuanyu, Cui, Luying, Sun, Haoxiu, Zhang, Dongzhi, Wang, Bojun, Fang, Lin, Guan, Xin, Yao, Yuanfei, Liu, Chao, Zhang, Yanqiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518977/
https://www.ncbi.nlm.nih.gov/pubmed/37743483
http://dx.doi.org/10.1186/s12916-023-03066-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518977/
https://www.ncbi.nlm.nih.gov/pubmed/37743483
http://dx.doi.org/10.1186/s12916-023-03066-4

Ejemplares similares